Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cytosorbents CorpCTSO · Entity 7625 | Chief Financial Officer | June 15, 2026 | June 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cytosorbents Corp
Report date June 15, 2026 · Filed June 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 638,113 |
Reported balance
After 2026-06-15 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-15 · Purchase · Acquired 100,000 · Balance 638,113 F1: The transaction reported on this Form 4 reflects an open market purchase made by the Reporting Person. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.40 to $0.45, inclusive. The Reporting Person undertakes to provide to CytoSorbents Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2: Includes (a) 110,000 restricted stock units ("RSUs"), which will be settled into the Issuer's common stock, par value $0.001 per share (the "Common Stock"), upon vesting upon the earlier of (i) a "Change In Control" of the Issuer, as defined in the Reporting Person's employment agreement (the "Employment Agreement"), or (ii) the fourth anniversary from the date of grant, or August 14, 2028, subject to the Reporting Person's continued service as of the applicable vesting date; F3: (continued from footnote 2) (b) 65,000 RSUs, of which 32,500 remain unvested as of the date hereof, and which shall vest as to one-half of the award on each of the first and second anniversaries of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date and will be settled into Common Stock upon vesting; F4: (continued from footnote 3) (c) 175,000 RSUs, which will be settled into Common Stock upon a "Change In Control" of the Issuer, as defined in the Reporting Person's Employment Agreement, subject to the Reporting Person's continued service as of the applicable vesting date; (d) 71,500 RSUs, which shall vest as to one-half of the award on each of the first and second anniversaries of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date and will be settled into Common Stock upon vesting; and F5: (continued from footnote 4) (e) 216,613 shares of Common Stock owned by the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: The transaction reported on this Form 4 reflects an open market purchase made by the Reporting Person. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.40 to $0.45, inclusive. The Reporting Person undertakes to provide to CytoSorbents Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4.
F2: Includes (a) 110,000 restricted stock units ("RSUs"), which will be settled into the Issuer's common stock, par value $0.001 per share (the "Common Stock"), upon vesting upon the earlier of (i) a "Change In Control" of the Issuer, as defined in the Reporting Person's employment agreement (the "Employment Agreement"), or (ii) the fourth anniversary from the date of grant, or August 14, 2028, subject to the Reporting Person's continued service as of the applicable vesting date;
F3: (continued from footnote 2) (b) 65,000 RSUs, of which 32,500 remain unvested as of the date hereof, and which shall vest as to one-half of the award on each of the first and second anniversaries of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date and will be settled into Common Stock upon vesting;
F4: (continued from footnote 3) (c) 175,000 RSUs, which will be settled into Common Stock upon a "Change In Control" of the Issuer, as defined in the Reporting Person's Employment Agreement, subject to the Reporting Person's continued service as of the applicable vesting date; (d) 71,500 RSUs, which shall vest as to one-half of the award on each of the first and second anniversaries of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date and will be settled into Common Stock upon vesting; and
F5: (continued from footnote 4) (e) 216,613 shares of Common Stock owned by the Reporting Person.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Axogen, Inc.
Report date December 11, 2023 · Filed December 13, 2023
Section 16 reporting ended · disclosed 2023-12-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 63,603 |
Ending reported balance
After 2023-12-11 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2023-12-11 · Sale · Disposed 1,410 · Balance 74,693 Row 2 · 2023-12-11 · Sale · Disposed 3,120 · Balance 71,573 Row 3 · 2023-12-11 · Sale · Disposed 7,970 · Balance 63,603 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 18, 2017 Filed Dec 20, 2017 23:53 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantRestricted Stock Units · Derivative | 7,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-015738 · edgar.xml · derivative · entry 2 MARIANI PETER J · CIK 0001222357 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,600 Underlying: Common Stock · 7,600 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of AxoGen, Inc. common stock. F3 · derivative.exercise_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 18, 2021 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 18, 2019 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F3 · derivative.expiration_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 18, 2021 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 18, 2019 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| December 18, 2017 Filed Dec 20, 2017 23:53 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantEmployee Stock Option (right to purchase) · Derivative | 45,000 | $0.00 Strike: $27.00 | $0.00 |
DisclosureSEC source: 0001179110-17-015738 · edgar.xml · derivative · entry 1 MARIANI PETER J · CIK 0001222357 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2027-12-18 F1 · derivative.exercise_date: All shares of AxoGen, Inc. common stock underlying the employee stock option will be fully vested on December 18, 2021 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 18, 2019 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter. Read SEC document |
| December 29, 2016 Filed Jan 3, 2017 21:40 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantEmployee Stock Option (right to purchase) · Derivative | 110,000 | $0.00 Strike: $8.95 | $0.00 |
DisclosureSEC source: 0001179110-17-000074 · edgar.xml · derivative · entry 1 MARIANI PETER J · CIK 0001222357 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires 2026-12-29 F1 · derivative.exercise_date: All shares of Common Stock underlying the employee stock option will be fully vested on December 29, 2020(4 years from the option grant date) based upon a vesting schedule whereby 25% of the aggregate shares vest on December 29, 2017(12 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter. Read SEC document |
| October 07, 2016 Filed Oct 14, 2016 19:13 UTC | Axogen, Inc. AXGN · Entity 4297 | PurchaseCommon Stock | 3,333 | $7.50 | $24,997.50 |
DisclosureSEC source: 0001179110-16-030713 · edgar.xml · nonDerivative · entry 1 MARIANI PETER J · CIK 0001222357 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,333 F1 · shares: The reporting person purchased these shares in his individual capacity and not through any directed share or other formal program in connection with an underwritten registered public offering of the Company. On October 7, 2016, the trade date for the public offering, the closing sale price reported by NASDAQ was $9.15 per share. The public offering closed on October 13, 2016 and the closing sale price reported by NASDAQ on such date was $8.72 per share. F1 · price: The reporting person purchased these shares in his individual capacity and not through any directed share or other formal program in connection with an underwritten registered public offering of the Company. On October 7, 2016, the trade date for the public offering, the closing sale price reported by NASDAQ was $9.15 per share. The public offering closed on October 13, 2016 and the closing sale price reported by NASDAQ on such date was $8.72 per share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.